News
Guideline Details Pharmacologic Management of COPD
Clinical practice guideline addresses 6 emerging questions around COPD management.
Your search for oral corticosteroids returned 99 results
Drugs in the Pipeline
Voclosporin NDA for Lupus Nephritis Submitted to FDA
The New Drug Application (NDA) for voclosporin (Aurinia Pharmaceuticals) has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
News
Dupixent Approval Expanded to Pediatric Patients With Atopic Dermatitis
The FDA has expanded the approval of Dupixent® (dupilumab; Regeneron and Sanofi) to include patients aged 6 to 11 years with moderate to severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
News
Guidelines Issued for Managing Eosinophilic Esophagitis
Topical glucocorticosteroids recommended over no treatment.
News
NIH Treatment Guidelines for COVID-19 Released
Recommendations on the management of coronavirus disease 2019 (COVID-19) were recently released by the National Institutes of Health (NIH) to help guide clinicians caring for patients with COVID-19.
News
ACAAI: Statement on Corticosteroid Use for Allergies, Asthma During COVID-19 Pandemic
The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.
Safety Alerts and Recalls
Certain Blister Packages of Sandimmune, Neoral Not Child Resistant
Certain blister packages of Sandimmune (cyclosporine capsules) and Neoral (cyclosporine capsules) may not meet child-resistant packaging requirements, according to manufacturer Novartis. The Company announced that it is working with the Consumer Product Safety Commission to address the packaging issue. In a press statement, Novartis stressed that there are no quality or efficacy issues with the…
AAAAI 2020, News
High Doses of Inhaled Corticosteroids Reduce Eosinophil Levels in Asthma
High doses of inhaled corticosteroids were associated with lower levels of eosinophils, which may interfere with the recommendation of some monoclonal antibodies in asthma treatment.
Dermatological Disorders, Drugs in the Pipeline
Dupilumab Gets Priority Review for Atopic Dermatitis in Patients Aged 6 to 11 Years
Dupixent, an interleukin-4 receptor alpha antagonist, is currently approved for moderate to severe atopic dermatitis in patients ≥12 years old who are not adequately controlled with topical prescription therapies or when they are not advisable.
Drugs in the Pipeline
Baricitinib Plus Topical Corticosteroids Effective in Atopic Dermatitis Study
Results showed that the 4mg dose of baricitinib plus TCS met the primary end point, with 31.5% of patients achieving EASI75 compared with 17.2% of patients in the placebo plus TCS group (P ≤.05).
